With third FDA approval, Seattle Genetics plans virtual launch of metastatic breast cancer drug amid coronavirus pandemic
Seattle Genetics has burst into the competitive market for breast cancer drugs, with a brain penetrating therapy: Tukysa.
The company — which has two armed antibodies, Adcetris and Padcev, in its arsenal — secured FDA approval for Tukysa on Friday, roughly four months ahead of the expected decision date. The list price for Tukysa will be $18,500/month and $111,000 per course of treatment, implying an expected duration of therapy of about 6 months.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.